Fu K K, Lam K N, Rayner P A
Int J Radiat Oncol Biol Phys. 1985 Dec;11(12):2119-24. doi: 10.1016/0360-3016(85)90092-6.
The influence of time sequence of cis-dichlorodiammine platinum (cisplatin) administration and continuous low dose rate irradiation (CLDRI) on their combined effects was studied in the SCC VII/SF tumor, a murine squamous cell carcinoma. Concurrent cisplatin i.p. infusion at 0.22 mg/kg/hr and CLDRI at 0.6 Gy/hr had a supraadditive effect on the survival of the SCC VII/SF tumor cells. Cisplatin by itself was more effective against the SCC VII/SF tumor when given by bolus injection than by continuous infusion i.p. However, when cisplatin at a dose of 6 mg/kg was given by bolus i.p. injection either immediately before or after CLDRI, the combined effects on the SCC VII/SF tumor cell survival were no more than additive. Exposure to CLDRI at 0.6 Gy/hr for 24 hours did not sensitize the SCC VII/SF tumor to subsequent treatment with cisplatin. These results suggest that when cisplatin is combined with CLDRI, for the optimal anti-tumor effect, it is best to infuse the cisplatin continuously during the course of CLDRI.
在小鼠鳞状细胞癌SCC VII/SF肿瘤中，研究了顺式二氯二氨铂（顺铂）给药时间顺序和连续低剂量率照射（CLDRI）对它们联合效应的影响。以0.22mg/kg/小时的剂量腹腔内持续输注顺铂并以0.6Gy/小时的剂量进行CLDRI，对SCC VII/SF肿瘤细胞的存活具有超相加效应。顺铂单次推注给药对SCC VII/SF肿瘤的疗效比腹腔内持续输注更好。然而，当在CLDRI之前或之后立即以6mg/kg的剂量腹腔内推注顺铂时，对SCC VII/SF肿瘤细胞存活的联合效应不超过相加作用。以0.6Gy/小时的剂量进行24小时的CLDRI照射，并不会使SCC VII/SF肿瘤对随后的顺铂治疗敏感。这些结果表明，当顺铂与CLDRI联合使用时，为了获得最佳抗肿瘤效果，最好在CLDRI过程中持续输注顺铂。
